SKAN Group (SKAN) Stock Overview
Provides isolators, cleanroom devices, and decontamination processes for pharmaceutical and chemical industries in Europe, the Americas, Asia, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
SKAN Community Fair Values
See what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
SKAN Group AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 48.60 |
| 52 Week High | CHF 77.80 |
| 52 Week Low | CHF 35.75 |
| Beta | 0.73 |
| 1 Month Change | 4.18% |
| 3 Month Change | 0.10% |
| 1 Year Change | -34.59% |
| 3 Year Change | -38.25% |
| 5 Year Change | 10.45% |
| Change since IPO | 604.35% |
Recent News & Updates
SKAN: Order Backlog And Dividend Payouts Will Support Future Returns
Analysts have reaffirmed their CHF 62.50 price target for SKAN Group, citing only very small tweaks to discount rate, revenue growth, profit margin and future P/E assumptions rather than any major change in the outlook. What's in the News The Board of Directors plans to propose a dividend of CHF 0.22 per share for approval at the Annual General Meeting on May 7, 2026, corresponding to a 30% payout ratio.SKAN: Order Backlog And Dividend Policy Will Support Future Returns
Analysts have kept their CHF 62.50 price target on SKAN Group unchanged, citing a slightly lower discount rate, more cautious assumptions on revenue growth and profit margins, and a higher future P/E multiple in their updated models. What's in the News The Board of Directors plans to propose a dividend of CHF 0.22 per share for approval at the Annual General Meeting on May 7, 2026.Recent updates
Shareholder Returns
| SKAN | CH Life Sciences | CH Market | |
|---|---|---|---|
| 7D | -7.4% | 0.9% | 1.2% |
| 1Y | -34.6% | -10.9% | 7.1% |
Return vs Industry: SKAN underperformed the Swiss Life Sciences industry which returned -10.9% over the past year.
Return vs Market: SKAN underperformed the Swiss Market which returned 7.1% over the past year.
Price Volatility
| SKAN volatility | |
|---|---|
| SKAN Average Weekly Movement | 6.2% |
| Life Sciences Industry Average Movement | 6.1% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in CH Market | 7.9% |
| 10% least volatile stocks in CH Market | 2.4% |
Stable Share Price: SKAN's share price has been volatile over the past 3 months compared to the Swiss market.
Volatility Over Time: SKAN's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of Swiss stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1968 | 1,647 | Jonas Greutert | skan.com/de/home/ |
SKAN Group AG, together with its subsidiaries, provides isolators, cleanroom devices, and decontamination processes for pharmaceutical and chemical industries in Europe, the Americas, Asia, and internationally. It operates in two segments, Equipment and Solutions; and Services and Consumables. The company offers accessories, biological indicators, digital ventures, isolators, cleanroom, laminar flow, particle counter, personal protective equipment, safety workbench, transfer systems, and fume cupboard.
SKAN Group AG Fundamentals Summary
| SKAN fundamental statistics | |
|---|---|
| Market cap | CHF 1.13b |
| Earnings (TTM) | CHF 16.27m |
| Revenue (TTM) | CHF 333.34m |
Is SKAN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SKAN income statement (TTM) | |
|---|---|
| Revenue | CHF 333.34m |
| Cost of Revenue | CHF 83.64m |
| Gross Profit | CHF 249.70m |
| Other Expenses | CHF 233.43m |
| Earnings | CHF 16.27m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Aug 18, 2026
| Earnings per share (EPS) | 0.72 |
| Gross Margin | 74.91% |
| Net Profit Margin | 4.88% |
| Debt/Equity Ratio | 99.0% |
How did SKAN perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/11 18:08 |
| End of Day Share Price | 2026/06/11 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
SKAN Group AG is covered by 8 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Thomas Meyer | Baader Helvea Equity Research |
| Leonildo Delgado | Baader Helvea Equity Research |
| Volker Bosse | Baader Helvea Equity Research |